Filter posts

Indiana Governor Signs Bill that Supports Transparent Communication

Indiana Governor Mike Pence has signed bipartisan legislation enabling retail pharmacies within his state to …

FDA Week: For Biologics, A Name Isn't Just A Name (Jim Greenwood op-ed)

What is in a name? Names help make medicinal products more easily distinguishable by doctors, …

BIO Responds to GPhA Citizen Petition on Biosimilars Naming

Last September, the Generic Pharmaceutical Association (GPhA) filed a Citizen Petition with the FDA, requesting …

Washington Gov. Jay Inslee to Keynote BIO Convention in China

Next month, BIO will be hosting our 3rd Annual BIO Convention in China, November 11-13. We are …

State Legislation Needed For Substitution of Interchangeable Biologics

A great deal of the media coverage relating to California’s Senate Bill 598  neglects to …

California Continues Responsible Support for Interchangeability of Biologic Drugs

Yesterday, California’s State Assembly Committee on Appropriations took another decisive step when they unanimously voted …

Data Exclusivity Protects Innovators and Assures Investors

Biotechnology companies must have some certainty that they can protect their investment in the development …

Biosimilars Ahead, Proceed with Caution

By Richard M. Dolinar, M.D., Chairman, Alliance for Safe Biologic Medicines In today’s budget-constrained world, …

Industry Regulatory Issues to be Highlighted at 2012 BIO International Convention

In the words of BIO’s Andrew Emmett, Managing Director, Science & Regulatory Affairs, ‘2012 is …

BIO IP Counsels Conference Agenda Topics

Join us in Austin for BIO’s Intellectual Property Counsels Committee Conference on April 16-18.  Agenda …